Scholar Rock Holding Corporation (SRRK)
Price:
47.22 USD
( + 0.20 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
BioNTech SE
VALUE SCORE:
6
2nd position
ADMA Biologics, Inc.
VALUE SCORE:
11
The best
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
DESCRIPTION
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
NEWS
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%
fool.com
2026-02-22 12:37:02Redmile Group added 1,316,390 shares of Scholar Rock Holding Corporation in the fourth quarter; the estimated trade value was $49.37 million based on quarterly average prices. Meanwhile, the quarter-end position value rose by $84.58 million, reflecting both new purchases and stock price changes.
Insider Selling: Scholar Rock (NASDAQ:SRRK) General Counsel Sells $445,757.40 in Stock
defenseworld.net
2026-02-22 04:32:54Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) General Counsel Junlin Ho sold 9,580 shares of the firm's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total value of $445,757.40. Following the transaction, the general counsel owned 241,545 shares in the company,
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2026-02-13 16:15:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the Company granted inducement equity awards covering an aggregate of 114,668 shares of its common stock to seven newly hired employees, consisting of inducement stock options to purchase an aggregate of 64,226 shares of common stock and inducement restricted stock units, covering an aggregate of 50,442 shares of its common stock. The awards are subject to all terms and conditions and other provis.
Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
businesswire.com
2026-02-10 08:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website at http://investors.scholarrock.com. To participate via telep.
Scholar Rock Chief Scientific Officer Conducts Multiple Sales Throughout January 2026
fool.com
2026-02-01 02:12:50Mo Qatanani sold 14,898 shares directly for a transaction value of approximately $695,938 on Jan. 22, 2026, at a weighted average price of $46.71 per share. The sale represented 14.82% of Qatanani's direct holdings, reducing direct ownership to 85,660 shares, which equates to 0.08% of shares outstanding.
12,008 Shares in Scholar Rock Holding Corporation $SRRK Acquired by SG Americas Securities LLC
defenseworld.net
2026-01-25 05:26:42SG Americas Securities LLC purchased a new stake in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 12,008 shares of the company's stock, valued at approximately $447,000. Other large investors have also recently made
Mo Qatanani Sells 13,112 Shares of Scholar Rock (NASDAQ:SRRK) Stock
defenseworld.net
2026-01-18 05:49:00Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) insider Mo Qatanani sold 13,112 shares of the company's stock in a transaction that occurred on Wednesday, January 14th. The shares were sold at an average price of $45.20, for a total transaction of $592,662.40. Following the completion of the transaction, the insider owned 108,964 shares
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2026-01-16 16:15:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 35,200 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 20,400 shares of common stock and inducement restricted stock units, covering an aggregate of 14,800 shares of its common stock. The awards are subject to all terms and conditions and other provision.
Scholar Rock Holding Corporation (SRRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
seekingalpha.com
2026-01-12 13:15:59Scholar Rock Holding Corporation (SRRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Scholar Rock Highlights 2026 Strategic Priorities
businesswire.com
2026-01-12 07:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today provided a corporate update and highlighted its strategic priorities for 2026. “We believe 2026 will be a transformative year for Sc.
Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Consensus Recommendation of “Buy” by Brokerages
defenseworld.net
2026-01-07 01:30:44Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) has been assigned a consensus rating of "Buy" from the sixteen brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and four have given a strong buy recommendation
Scholar Rock: Apitegromab's Path Forward Remains Intact, Maintaining Buy Rating
seekingalpha.com
2026-01-05 23:59:22I maintain a buy rating on Scholar Rock, raising my target price to $97, reflecting increased confidence in apitegromab's approval and commercial prospects. FDA setbacks are manufacturing-related, not clinical, with no new efficacy or safety concerns; remediation and a second CDMO are underway. Topline phase 3 data support apitegromab's novel mechanism and broad label potential, materially expanding SRRK's addressable market and pricing power.
Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference
businesswire.com
2026-01-05 08:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12 at 7:30 a.m. PST (.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2025-12-13 10:57:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), today announced that the company granted inducement equity awards covering an aggregate of 7,800 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 4,457 shares of common stock and inducement restricted stock units, covering an aggregate of 3,343 shares of its common stock. The awards are subject to all terms and conditions and other provisions.
Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Average Rating of “Buy” by Brokerages
defenseworld.net
2025-12-13 01:16:52Shares of Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) have earned a consensus rating of "Buy" from the sixteen research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and four have issued a strong buy recommendation
Scholar Rock Holding Corporation $SRRK Stock Holdings Boosted by Federated Hermes Inc.
defenseworld.net
2025-12-12 03:52:47Federated Hermes Inc. increased its position in Scholar Rock Holding Corporation (NASDAQ: SRRK) by 10,809.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 241,000 shares of the company's stock after acquiring an additional 238,791 shares during the period.
No data to display
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%
fool.com
2026-02-22 12:37:02Redmile Group added 1,316,390 shares of Scholar Rock Holding Corporation in the fourth quarter; the estimated trade value was $49.37 million based on quarterly average prices. Meanwhile, the quarter-end position value rose by $84.58 million, reflecting both new purchases and stock price changes.
Insider Selling: Scholar Rock (NASDAQ:SRRK) General Counsel Sells $445,757.40 in Stock
defenseworld.net
2026-02-22 04:32:54Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) General Counsel Junlin Ho sold 9,580 shares of the firm's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total value of $445,757.40. Following the transaction, the general counsel owned 241,545 shares in the company,
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2026-02-13 16:15:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the Company granted inducement equity awards covering an aggregate of 114,668 shares of its common stock to seven newly hired employees, consisting of inducement stock options to purchase an aggregate of 64,226 shares of common stock and inducement restricted stock units, covering an aggregate of 50,442 shares of its common stock. The awards are subject to all terms and conditions and other provis.
Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
businesswire.com
2026-02-10 08:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website at http://investors.scholarrock.com. To participate via telep.
Scholar Rock Chief Scientific Officer Conducts Multiple Sales Throughout January 2026
fool.com
2026-02-01 02:12:50Mo Qatanani sold 14,898 shares directly for a transaction value of approximately $695,938 on Jan. 22, 2026, at a weighted average price of $46.71 per share. The sale represented 14.82% of Qatanani's direct holdings, reducing direct ownership to 85,660 shares, which equates to 0.08% of shares outstanding.
12,008 Shares in Scholar Rock Holding Corporation $SRRK Acquired by SG Americas Securities LLC
defenseworld.net
2026-01-25 05:26:42SG Americas Securities LLC purchased a new stake in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 12,008 shares of the company's stock, valued at approximately $447,000. Other large investors have also recently made
Mo Qatanani Sells 13,112 Shares of Scholar Rock (NASDAQ:SRRK) Stock
defenseworld.net
2026-01-18 05:49:00Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) insider Mo Qatanani sold 13,112 shares of the company's stock in a transaction that occurred on Wednesday, January 14th. The shares were sold at an average price of $45.20, for a total transaction of $592,662.40. Following the completion of the transaction, the insider owned 108,964 shares
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2026-01-16 16:15:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 35,200 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 20,400 shares of common stock and inducement restricted stock units, covering an aggregate of 14,800 shares of its common stock. The awards are subject to all terms and conditions and other provision.
Scholar Rock Holding Corporation (SRRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
seekingalpha.com
2026-01-12 13:15:59Scholar Rock Holding Corporation (SRRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Scholar Rock Highlights 2026 Strategic Priorities
businesswire.com
2026-01-12 07:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today provided a corporate update and highlighted its strategic priorities for 2026. “We believe 2026 will be a transformative year for Sc.
Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Consensus Recommendation of “Buy” by Brokerages
defenseworld.net
2026-01-07 01:30:44Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) has been assigned a consensus rating of "Buy" from the sixteen brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and four have given a strong buy recommendation
Scholar Rock: Apitegromab's Path Forward Remains Intact, Maintaining Buy Rating
seekingalpha.com
2026-01-05 23:59:22I maintain a buy rating on Scholar Rock, raising my target price to $97, reflecting increased confidence in apitegromab's approval and commercial prospects. FDA setbacks are manufacturing-related, not clinical, with no new efficacy or safety concerns; remediation and a second CDMO are underway. Topline phase 3 data support apitegromab's novel mechanism and broad label potential, materially expanding SRRK's addressable market and pricing power.
Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference
businesswire.com
2026-01-05 08:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12 at 7:30 a.m. PST (.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2025-12-13 10:57:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), today announced that the company granted inducement equity awards covering an aggregate of 7,800 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 4,457 shares of common stock and inducement restricted stock units, covering an aggregate of 3,343 shares of its common stock. The awards are subject to all terms and conditions and other provisions.
Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Average Rating of “Buy” by Brokerages
defenseworld.net
2025-12-13 01:16:52Shares of Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) have earned a consensus rating of "Buy" from the sixteen research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and four have issued a strong buy recommendation
Scholar Rock Holding Corporation $SRRK Stock Holdings Boosted by Federated Hermes Inc.
defenseworld.net
2025-12-12 03:52:47Federated Hermes Inc. increased its position in Scholar Rock Holding Corporation (NASDAQ: SRRK) by 10,809.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 241,000 shares of the company's stock after acquiring an additional 238,791 shares during the period.